
    
      This is a phase I trial to assess the safety of a dose escalation of hCD40L-expressing
      autologous tumor cells with a fixed dose of recombinant hIL-2 gene transduced autologous
      leukemic blasts. All eligible patients will be treated with a minimum of three and up to six
      injections. There will be no use of placebo or control subjects.
    
  